Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Unique Punishment:...

    Unique Punishment: High Court asks Pharma Company to deposit Rs 1.50 crore towards Kerala Relief Fund

    Written by Ruby Khatun Khatun Published On 2018-09-01T12:01:30+05:30  |  Updated On 1 Sept 2018 12:01 PM IST
    Unique Punishment: High Court asks Pharma Company to deposit Rs 1.50 crore towards Kerala Relief Fund

    Mumbai: The Bombay High Court has ordered a pharmaceutical company to deposit Rs 1.50 crore towards the Kerala Chief Minister's Fund for flood relief work in a trademark infringement case.


    Justice S J Kathawalla on August 28 held that Galpha Laboratories was a "habitual infringer" of various medicinal products, whose trademarks have been registered by other pharma companies.


    The court was hearing a suit filed by Glenmark Pharmaceuticals against Galpha Laboratories for allegedly infringing upon its medicinal cream products.

    According to Glenmark, the defendant companies were selling a cream 'Clodid B' with the same design and pattern as that of Glenmark's 'Candid B' cream.

    The court accepted the arguments and noted that there has been a systematic copy of Glenmark Pharmaceutical's products.

    "Drugs are not sweets. Pharmaceutical companies which provide medicines for the health of the consumers have a special duty of care towards them," Justice Kathawalla said in his order.

    "These companies, in fact, have a greater responsibility towards the general public. However, nowadays, the corporate and financial goals of such companies cloud the decision of its executives whose decisions are incentivized by profits, more often than not, at the cost of public health. This case is a perfect example of just that," the court said.

    The court directed Galpha Laboratories to deposit a sum of Rs 1.50 crore towards the Kerala Chief Minister's Fund to be used for the relief work in the aftermath of the recent floods.

    "Considering the catastrophe that has hit Kerala recently and the fact that Kerala flood situation is a disaster of serious nature, which has been categorized as L3 Level of disaster by the National Disaster Management Guidelines, Galpha Laboratories should pay the costs of Rs 1,50,00,000 as a donation to the Kerala Chief Minister Distress Relief Fund," the court ordered.

    Glenmark in its suit claimed that this was not the first time that Galpha Laboratories was indulging in such infringements and claimed that they were habitual infringers.

    Taking note of the fact that several other pharma companies have also filed cases against Galpha Laboratories for alleged infringement in various courts, Justice Kathawalla said, "There is, therefore, no doubt in my mind that the Defendant No.2 (Galpha) is a habitual offender with a set modus operandi of copying brands of other companies to make profits."

    The court initially said that Galpha would have to pay the sum to Glenmark. However, Glenmark requested the court to direct Galpha Laboratories to deposit the sum in any NGO.

    Following this, Justice Kathawalla directed for the money to be deposited in the Kerala Chief Minister's Fund.

    The court also accepted Galpha Laboratories' assurance that it would not infringe on any other products of any other company in the future.
    Bombay High CourtCandid BClodid BGalpha LaboratoriesGlenmark PharmaceuticalsGuiltyhabitual infringersHCinfringement caseJustice S J KathawallaKerala Chief Minister's FundKerala flood reliefmedicinal productsNational Disaster Management GuidelinesNGOtrademark infringement casetrademarks
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok